 | • レポートコード：MRC2303K106 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の感染症診断市場規模が、予測期間中、CAGR 3.79％で増大すると予測されています。本レポートでは、感染症診断の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、用途別（肝炎、ヒト免疫不全ウイルス（HIV）、病院内感染症、結核（TB）、その他）分析、製品別（アッセイ・キット・試薬、器具、サービス・ソフトウェア）分析、技術別（ポリメラーゼ連鎖反応（PCR）、等温核酸増幅技術（INAAT）、免疫診断、DNAマイクロアレイ、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Biomérieux SA、Abbott Laboratories、Becton, Dickinson and Company、Bio-Rad Laboratories、Danaher Corporation、F. Hoffmann-La Roche AG、Siemens Healthineers、Thermo Fisher Scientific、Quidel Corporation、DiaSorin SpA (Luminex)、Trinity Biotech PLC、Quest Diagnostics、Sysmex Corporation、Ortho Clinical Diagnostics、Seegene Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の感染症診断市場規模：用途別 - 肝炎における市場規模 - ヒト免疫不全ウイルス（HIV）における市場規模 - 病院内感染症における市場規模 - 結核（TB）における市場規模 - その他用途における市場規模 ・世界の感染症診断市場規模：製品別 - アッセイ・キット・試薬の市場規模 - 器具の市場規模 - サービス・ソフトウェアの市場規模 ・世界の感染症診断市場規模：技術別 - ポリメラーゼ連鎖反応（PCR）における市場規模 - 等温核酸増幅技術（INAAT）における市場規模 - 免疫診断における市場規模 - DNAマイクロアレイにおける市場規模 - その他技術における市場規模 ・世界の感染症診断市場規模：地域別 - 北米の感染症診断市場規模 アメリカの感染症診断市場規模 カナダの感染症診断市場規模 メキシコの感染症診断市場規模 … - ヨーロッパの感染症診断市場規模 ドイツの感染症診断市場規模 イギリスの感染症診断市場規模 フランスの感染症診断市場規模 … - アジア太平洋の感染症診断市場規模 中国の感染症診断市場規模 日本の感染症診断市場規模 インドの感染症診断市場規模 … - 南米/中東の感染症診断市場規模 南アフリカの感染症診断市場規模 ブラジルの感染症診断市場規模 アルゼンチンの感染症診断市場規模 … ・競争状況 ・市場機会・将来動向 |
The infectious disease diagnostics market is expected to register a CAGR of 3.79% over the forecast period.
The market for infectious illness diagnostics was considerably affected by the COVID-19 pandemic. The market under study benefited from the high infection rates among COVID-19 patients. For instance, in February 2022, Mylab Discovery Solutions released CoviSwift, a point-of-care (POC) RT-PCR testing system that may be used in small labs, in-hospital labs, airports, and communities. Additionally, in March 2020, BioMedomics released PoC COVID-19 test that can detect antibodies in blood within 15 minutes. Furthermore, in March 2020, Abbott introduced the RealTime SARS-CoV-2 assay, a PCR-based test for diagnosing COVID-19. As the incidence of coronavirus increased, there was a greater need for diagnostic tools for infectious diseases during the pandemic. Additionally, many diagnostic labs and testing facilities opened, which broadened the market’s potential. For instance, in June 2020, the Union Minister of Health and Family Welfare introduced India’s first mobile I-Lab (Infectious disease diagnostic lab) for COVID-19 testing. Hence, in the early phase, COVID-19 impacted the market considerably; however, currently, the demand for diagnostic tools for infectious diseases has slowed down and is expected to have stable growth during the forecast period of the study.
The rising prevalence of infectious diseases, the shift in emphasis from centralized laboratories to point-of-care testing, and rising R&D activity on infectious disease diagnostics are other important drivers of market expansion. Rapid diagnostics for the detection of diseases are evolving as a result of scientific research and development efforts in developing novel technologies and techniques, including mass spectrometry and next-generation sequencing (NGS), fueling market expansion. For instance, according to an article by Frontiers in February 2022, non-typhoidal Salmonella is a common cause of bacterial enteritis in humans. It causes almost 93.8 million cases of gastroenteritis globally each year. The increasing preference of end users for point-of-care testing is also projected to fuel market expansion. Point-of-care diagnostics offer quick, useful information for patient care where the disease is being experienced. As a result, several firms are concentrating on research and development initiatives to create point-of-care diagnostic solutions for developing nations. The major firms are constantly updating their product lines through introducing new goods, joint ventures with third parties, mergers, and acquisitions, all of which will contribute to the worldwide study market’s expansion. For instance, in December 2021, Roche launched the first infectious disease tests on the Cobas 5800 System, a new molecular laboratory instrument, in countries accepting the CE mark. Similarly, in May 2021, Torus Biosystems revealed the USD 25 million series financing to advance infectious disease diagnostics across healthcare settings.
Thus, factors such as the rising prevalence of infectious diseases and increasing initiatives by major market players are expected to drive market growth over the forecast period. However, inadequate reimbursements and rising healthcare costs limiting the use of novel diagnostic techniques are restraining the market’s growth.
Infectious Disease Diagnostics Market Trends
The Human Immunodeficiency Virus (HIV) Segment is Expected to Hold a Significant Share of the Market Over the Forecast Peiod
The human immunodeficiency virus segment is anticipated to witness significant growth during the forecast period of the study. The Minority of HIV/AIDS Fund (MHAF), United States Department of Health and Human Services Statistics, updated in June 2021, estimates that approximately 37.6 million people are living with HIV worldwide in 2020, of whom 35.9 million were adults and 1.7 million were children (under the age of 15). According to the same source, 1.5 million people will have contracted HIV globally in 2020. The market is expanding due to the rising prevalence of HIV and the demand for diagnostic tests and detection.
Additionally, in August 2021, the Human Rights Campaign (HRC) Foundation and “Us Helping Us” started the first in-home HIV testing program for residents in the United States. It is anticipated that the increased awareness about HIV and rising initiatives taken by various organizations worldwide will support the market growth during the forecast period.
It is also anticipated that new research and developments, technological advancements, and the introduction of technologically enhanced goods by key competitors will accelerate the market’s expansion. For instance, in April 2021, Altona Diagnostics One introduced an in-vitro diagnostic test that identifies and quantifies the human immunodeficiency virus (HIV) specific RNA in human plasma. It was based on real-time RT-PCR technology, and the test was known as the 1.5 AltoStar HIV RT-PCR Kit.
Therefore, due to increasing HIV infections, new research and developments, and technological advancements, the Human Immunodeficiency Virus (HIV) segment is expected to witness significant growth over the forecast period.
North America is Anticipated to Observe Significant Market Growth Over the Forecast Period
North America, is expected to hold a significant share of the market. The major factors contributing to the market growth are the increasing prevalence of infectious diseases, high expenditure on healthcare, and an increase in awareness among the population regarding the availability of diagnostic devices. For instance, according to information released by CDC, the 2021 flu season resulted in 9 million illnesses, 4 million medical visits, and 10,000 hospitalizations in the United States. In the upcoming years, market growth is predicted to be positively impacted by the rising burden of diseases.
In addition, in June 2021 the FDA registered Dipanjan Pan’s laboratory at the University of Maryland School of Medicine (UMSOM) as an approved laboratory development site for RNA Disease Diagnostics Inc.’s Antisense COVID-19 molecular diagnostic test. The market is therefore anticipated to have significant expansion in the region over the course of the projected period in light of the aforementioned considerations.
Additionally, the market expansion in the nation will be accelerated by strategic activities including collaborations, acquisitions, grant programmes, and others. For instance, in July 2021, Omega Specialty Nurses (OSN), House of Sophrosyne, and the Viral Hepatitis Care Network in Ontario have received grants from the 2021 CONNECT-C Grant Program from Gilead Sciences Canada, Inc. to expand the number of hepatitis screening centres across the nation. This is expected to improve the diagnosis of disease and adaptability of product and thus drives the market.
The market is also driven by expanding investments for improving disease model analysis. To develop linkages between the academic community, business community, and the governmental sector. For instance, in April 2021, the government of Canada formed five multidisciplinary infectious disease modelling networks with a total expenditure of USD 10 million. The findings will enable Canada to better respond to potential threats to public health, which will spur the industry to expand. The coordination of infectious disease modelling will also be considerably improved.
Therefore, due to factors such as increasing prevalence of infectious diseases, expanding investments for improving disease model analysis, and strategic activities including collaborations, acquisitions, grant programmes, and others, the growth of the studied market is anticipated in the North American region.
Infectious Disease Diagnostics Market Competitor Analysis
The infectious disease diagnostics market is highly fragmented, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some key players in the market are Danaher Corporation, Veracyte Inc., Abbott Laboratories, BioMérieux SA, F. Hoffmann-La Roche Ltd, and Becton, Dickinson and Company.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Infectious Diseases
4.2.2 Shift in Focus from Centralized Laboratories to Decentralized Point-of-Care Testing
4.2.3 Research on Infectious Disease Diagnostics
4.3 Market Restraints
4.3.1 Inadequate Reimbursements
4.3.2 Rising Healthcare Costs Limiting the Use of Novel Diagnostic Techniques
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size By Value- USD million)
5.1 By Application
5.1.1 Hepatitis
5.1.2 Human Immunodeficiency Virus (HIV)
5.1.3 Chlamydia Trachomatis Genital Infection and Gonorrhea (CT/NG)
5.1.4 Hospital-acquired Infections
5.1.5 Human Papillomavirus (HPV)
5.1.6 Tuberculosis (TB)
5.1.7 Influenza
5.1.8 Other Infectious Diseases
5.2 By Product
5.2.1 Assays, Kits, and Reagents
5.2.2 Instruments
5.2.3 Services and Software
5.3 By Technology
5.3.1 Polymerase Chain Reaction (PCR)
5.3.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
5.3.3 Immunodiagnostics
5.3.4 DNA Microarray
5.3.5 Clinical Microbiology
5.3.6 DNA Sequencing and Next-Generation Sequencing (NGS)
5.3.7 Other Technologies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biomérieux SA
6.1.2 Abbott Laboratories
6.1.3 Becton, Dickinson and Company
6.1.4 Bio-Rad Laboratories
6.1.5 Danaher Corporation
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Siemens Healthineers
6.1.8 Thermo Fisher Scientific
6.1.9 Quidel Corporation
6.1.10 DiaSorin SpA (Luminex)
6.1.11 Trinity Biotech PLC
6.1.12 Quest Diagnostics
6.1.13 Sysmex Corporation
6.1.14 Ortho Clinical Diagnostics
6.1.15 Seegene Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
